281 related articles for article (PubMed ID: 34735741)
1. A proposal for managing bleeding in patients on therapeutic factor XI(a) inhibitors.
Salomon O; Gailani D
J Thromb Haemost; 2022 Jan; 20(1):32-38. PubMed ID: 34735741
[TBL] [Abstract][Full Text] [Related]
2. Targeting factor XI and factor XIa to prevent thrombosis.
Gailani D; Gruber A
Blood; 2024 Apr; 143(15):1465-1475. PubMed ID: 38142404
[TBL] [Abstract][Full Text] [Related]
3. The hemostatic role of factor XI.
Puy C; Rigg RA; McCarty OJ
Thromb Res; 2016 May; 141 Suppl 2(Suppl 2):S8-S11. PubMed ID: 27207433
[TBL] [Abstract][Full Text] [Related]
4. Factor XI and coagulation. Factor XI inhibitors - antithrombotic perspectives.
Vlădăreanu AM; Roşca A
Rom J Intern Med; 2024 Jun; 62(2):91-100. PubMed ID: 38153875
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in the discovery and development of factor XI/XIa inhibitors.
Al-Horani RA; Afosah DK
Med Res Rev; 2018 Sep; 38(6):1974-2023. PubMed ID: 29727017
[TBL] [Abstract][Full Text] [Related]
6. Factor XI replacement for inherited factor XI deficiency in routine clinical practice: results of the HEMOLEVEN prospective 3-year postmarketing study.
Bauduer F; de Raucourt E; Boyer-Neumann C; Trossaert M; Beurrier P; Faradji A; Peynet J; Borg JY; Chamouni P; Chatelanaz C; Henriet C; Bridey F; Goudemand J;
Haemophilia; 2015 Jul; 21(4):481-9. PubMed ID: 25817556
[TBL] [Abstract][Full Text] [Related]
7. Ongoing risk of thrombosis with factor XI concentrate: 5 years experience in two centres.
Batty P; Honke A; Bowles L; Hart DP; Pasi KJ; Uprichard J; Austin SK
Haemophilia; 2015 Jul; 21(4):490-5. PubMed ID: 25855341
[TBL] [Abstract][Full Text] [Related]
8. Factor XI promotes hemostasis in factor IX-deficient mice.
Mohammed BM; Cheng Q; Matafonov A; Monroe DM; Meijers JCM; Gailani D
J Thromb Haemost; 2018 Oct; 16(10):2044-2049. PubMed ID: 30007049
[TBL] [Abstract][Full Text] [Related]
9. The Management of Factor XI Deficiency in Pregnancy.
Davies J; Kadir R
Semin Thromb Hemost; 2016 Oct; 42(7):732-740. PubMed ID: 27699729
[TBL] [Abstract][Full Text] [Related]
10. Fluorescent Activity-Based Probe To Image and Inhibit Factor XIa Activity in Human Plasma.
Modrzycka S; Kołt S; Adams TE; Potoczek S; Huntington JA; Kasperkiewicz P; Drąg M
J Med Chem; 2023 Mar; 66(6):3785-3797. PubMed ID: 36898159
[TBL] [Abstract][Full Text] [Related]
11. Coagulation factor XI as a novel target for antithrombotic treatment.
Löwenberg EC; Meijers JC; Monia BP; Levi M
J Thromb Haemost; 2010 Nov; 8(11):2349-57. PubMed ID: 20727068
[TBL] [Abstract][Full Text] [Related]
12. In vitro comparison of the effect of two factor XI (FXI) concentrates on thrombin generation in major FXI deficiency.
Pike GN; Cumming AM; Hay CR; Sempasa B; Sutherland M; Thachil J; Burthem J; Bolton-Maggs PH
Haemophilia; 2016 May; 22(3):403-10. PubMed ID: 26558335
[TBL] [Abstract][Full Text] [Related]
13. Recombinant factor VIIa to prevent surgical bleeding in factor XI deficiency.
O'Connell NM; Riddell AF; Pascoe G; Perry DJ; Lee CA
Haemophilia; 2008 Jul; 14(4):775-81. PubMed ID: 18384352
[TBL] [Abstract][Full Text] [Related]
14. Bleeding phenotype and correlation with factor XI (FXI) activity in congenital FXI deficiency: results of a retrospective study from a single centre.
Santoro C; Di Mauro R; Baldacci E; De Angelis F; Abbruzzese R; Barone F; Bochicchio RA; Ferrara G; Guarini A; Foà R; Mazzucconi MG
Haemophilia; 2015 Jul; 21(4):496-501. PubMed ID: 25623511
[TBL] [Abstract][Full Text] [Related]
15. Factor XI Deficiency.
Duga S; Salomon O
Semin Thromb Hemost; 2009 Jun; 35(4):416-25. PubMed ID: 19598070
[TBL] [Abstract][Full Text] [Related]
16. Gene targeting in hemostasis. factor XI.
Gailani D
Front Biosci; 2001 Feb; 6():D201-7. PubMed ID: 11171549
[TBL] [Abstract][Full Text] [Related]
17. Clinical Evaluation of Factor XIa Inhibitor Drugs: JACC Review Topic of the Week.
Harrington J; Piccini JP; Alexander JH; Granger CB; Patel MR
J Am Coll Cardiol; 2023 Feb; 81(8):771-779. PubMed ID: 36813377
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of factor XI (FXI) concentrate use in patients with FXI deficiency: a single-centre experience of 19 years.
Ling G; Kagdi H; Subel B; Chowdary P; Gomez K
Haemophilia; 2016 May; 22(3):411-8. PubMed ID: 26663472
[TBL] [Abstract][Full Text] [Related]
19. Pharmacology and Clinical Development of Factor XI Inhibitors.
Greco A; Laudani C; Spagnolo M; Agnello F; Faro DC; Finocchiaro S; Legnazzi M; Mauro MS; Mazzone PM; Occhipinti G; Rochira C; Scalia L; Capodanno D
Circulation; 2023 Mar; 147(11):897-913. PubMed ID: 36913497
[TBL] [Abstract][Full Text] [Related]
20. Plasma Kallikrein Contributes to Coagulation in the Absence of Factor XI by Activating Factor IX.
Visser M; van Oerle R; Ten Cate H; Laux V; Mackman N; Heitmeier S; Spronk HMH
Arterioscler Thromb Vasc Biol; 2020 Jan; 40(1):103-111. PubMed ID: 31766871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
